Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Evofem Biosciences, Inc.: Filed Certificate of Designations creating Series E-1 Preferred Stock, part of Amended and Restated Articles of Incorporation (effective 2023-08-07).
- Change
- charter amendment
- Effective
- 2023-08-07
Exact text from the filing
On August 7, 2023 the Company filed the Certificate of Designations creating the Series E-1 Preferred Stock. The Certificate of Designations, which forms a part of the Company’s Amended and Restated Articles of Incorporation, specifies the terms of the Series E-1 Preferred Stock.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Evofem Biosciences, Inc. entered into Securities Purchase Agreement with certain investors valued at Notes in aggregate original principal amount of $1,000,000 and Warrants to purchase 799,999 shares o (effective 2023-08-04).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- certain investors
- Value
- Notes in aggregate original principal amount of $1,000,000 and Warrants to purchase 799,999 shares o
- Effective
- 2023-08-04
Exact text from the filing
On August 4, 2023, Evofem Biosciences, Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (“ SPA ”), with certain investors (the “ Investors ”) providing for the sale and issuance of senior subordinate convertible notes due in the aggregate original principal amount of $1,000,000 (the “ Notes ”) and warrants (“ Warrants ”) to purchase an aggregate 799,999 shares of Common Stock, par value $0.0001 per share (the “ Common Stock ”) (collectively, the “ Offering ”).
View on SEC.gov